BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Putting resources into Yourself: Self-awareness Techniques- Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- 7 Espresso Machines for Home Baristas
- Opening Potential: Self-awareness and Long lasting Learning
- Misjudged Objections For Solo Voyagers
- All that You Really want to Be aware of Dental Inserts Facilities
- Most loved Seared Chicken: Which Chain Rules?
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
